Radiosensitizer AK-2123 as modulating agent in the chemotherapy of experimental metastases.

Therapeutic effect of Cyclophosphamide (CPA) and radiosensitizer AK-2123 (AK) combination versus CPA alone in the same doses was investigated on transplanted LL carcinoma and B 16 melanoma. Antimetastatic efficacy of different doses of CPA and combined therapy was evaluated. Our data demonstrate that the effect of combined treatment by CPA at low uneffective doses (60 mg/kg, 40 mg/kg, 20 mg/kg at the 3rd and the 7th day after transplantation) and AK at low daily doses (1 mg/kg and 0.1 mg/kg for 3-9 days after transplantation) is equal or superior to the effect of CPA alone at the therapeutic dose (120 mg/kg).